{"ticker": {"uuid": "50d14756-dd0f-434b-9d95-0b5721cc6d60", "symbol": "ALKS", "name": "Alkermes Plc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T05:04:10+00:00", "published_display": "16 Jul 2026 05:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report Second Quarter Financial Results on July 28, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-report-second-quarter-financial-200000876.html", "source_name": "Business Wire", "published_at": "2026-07-14T20:00:00+00:00", "published_display": "14 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study", "summary": "Alkermes plc (NASDAQ: ALKS) announced positive interim results from its long-term extension study of alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue for adults with narcolepsy type 1 and 2. Participants in both groups demonst", "url": "https://www.sahmcapital.com/news/content/alkermes-says-lead-drug-maintains-wakefulness-benefits-in-long-term-narcolepsy-study-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T13:40:41", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $62", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQblJsN0d4cU1QX3hsV1FNZkJ6bGF0Q3hMbURnOHVQRjhuRUU4RF9FVmZjcEFQZm5zdWdHUjNvekdSN3lVUHpZOVhBOGl2QjJTMzM4YWdYUkQtUmFZSjZGcXBxNzNwT0REd3V2WHhQZVlrSW5LZkdZUlRUS2xSRmItN3NhNWRsUmZZZGM4OVRmQzVTZFVWYXoxdXJ5N2Izc3NvY1kxVUJwTDVTcnFha05raQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T09:48:01+00:00", "published_display": "14 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPc1BKVFJFM0RiYWNEbjl3dXlnNDR6T1lJWWtEanQ4VkZTaG9GQWNycVN5el80eVB3d3FBcng1TFpiSkNBOC1hLUoxQzEyZTVXZGxDQTAwREF2M1V0TjVCa0sycDJqQi1Tb05TNmd1bFp5MGotR3V6ODY3czNpTzJJRk9aLVpuaUxGTkxXSEJSMG5acC02dXIxc3RjTkljbTZPc25kWlVZTGYzeHBrcWIxd2FEZ2xGdXE3UkQ0MkRadjE?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-13T15:03:43+00:00", "published_display": "13 Jul 2026 15:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-public-apos-alixorexton-demonstrates-120109047.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:01:09+00:00", "published_display": "13 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes\u2019 Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-alixorexton-demonstrated-sustained-improvement-110000199.html", "source_name": "Business Wire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental narcolepsy pill from Alkermes keeps patients awake and alert for up to nine months", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOQzRMZ1A2YmZzdWEtbkVDT1J3M0tBZlp4d1BDUGJwMFpRUDU0alFpOFNrMWFRTHNFMHNjcFhWTEl4WTJWUVVtNm1hVjJjR2ZBRXp0RlRiMk5qZkdFYkpDZFFISzAyRDR6d1k4UVVNZGczdVZ3bUR5VUNlcHNrNFRHbXVoSF8yUW1iTlV5ellKa3JIYlV4ZlpNV1NaRnpFSGFhbTNLQWM2VzdfSVBRRlBTbzdXOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes Alkermes stock coverage with neutral rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbFNJMnpqQm5mbHpGenV5NGNrTC1YVXA3RHFUaXF0ZmQyOHBRSnhaQ3JmU1Z0N2ljNzFhRTJpejd0MWNWQm1LY0Jsd0dnZDdSZVE2OFdINTMzTlJaSDdKUGxZRFFWdzZVX0RxbGt0MUJpbE1NM0NpbGxHUjFTOExVZGpUVE1iV1FzMHZEaXlVS1Zpc0tYcXlQdHJEd25NNm1qd3FrUGJFVjZBbXFCRVpYaWdWS2FBSEVOLWRaWlZB?oc=5", "source_name": "Investing.com Australia", "published_at": "2026-07-13T08:52:04+00:00", "published_display": "13 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF S", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObnlqUm53SXFHMDlrbnVkVTZQTVVIRWNLVko0UElZSFFVYjltaVRKaDB0V1NuWEF6akFkZmQzRkhMY2wtc2xXMnNjTXNSWHp0VWtPTThlYjVLRkhySFhmWEpLdzQ5YmhkVmIxUjRRWEZNcHMyMEliRTFqVVF5OXhaZm9GOUFqZzF2NWRkNm9KU3BUM283TE4yRlNtWGNMT05xcW1KX1ZaX0xnSWUwUkhBZVV0eVBPSUhpeUE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T21:56:14+00:00", "published_display": "10 Jul 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T05:00:40+00:00", "published_display": "09 Jul 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Insider Sold Shares Worth $463,621, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alkermes-insider-sold-shares-worth-081501424.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:15:01+00:00", "published_display": "02 Jul 2026 08:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 Addition - What's Changed", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-alks-9-3-strong-140702068.html", "source_name": "Simply Wall St.", "published_at": "2026-06-30T14:07:02+00:00", "published_display": "30 Jun 2026 14:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Stock 7-Day Winning Spree: Stock Climbs 25%", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQOVVYaFpnRW9QNHZySEIyVEw5WnlrTVdWSm12aHh3MkVyVTFMQzdqNGhFaW5iVWxTUXlxSGE5RV9xR28wRzhhT2ZXUGJkTVJJMTFSM2w3WFRqOGQ5Qmx4eEsyaGNaY2F4bzU2enJJMVpjaVFnTS1Ma0JvYnljTm9Oc24td2EzeGxKaHBJU0NWcS1Ib1NqaGxJdGIxVmlMR3c1SGJXMWp2cFdfN0ZxbzI0Xw?oc=5", "source_name": "Trefis", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alkermes plc \u2013 NASDAQ:ALKS", "summary": "This article focuses on the enterprise value to EBIT forward for Alkermes plc (NASDAQ: ALKS). It appears to be a financial data point or analysis page from TradingView, providing an overview of this specific financial metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALKS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:40:29", "published_display": "28 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Stock On Fire: Up 25% With 7-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWlFpM0FQSE5MS0hjVTJSM2FPY1RRUWRHSzY1a3pGRlFRUUJWZlZWUWgtR1YtSlhjQmhPSXBEWjN3c3hQaFlkSjZZSHB1Q2s1RzktRWJ3OUhOQVRycWNNNHpYa3N0TDhRTm1XbHhJYkc1eGZQSHNtT3hKajIzTVVicW9tV3pqeHB4Z0lzal9WdDZreGZpdjk1akRrcXMxZkJVRGJfbVcxRmNVQkd3bjhRNTBPdVBsQ2tYV0JtOHR4a3g1UQ?oc=5", "source_name": "Trefis", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at 45.76 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOSnU0WXlhLXRFWEhpZE50Vk93QlVLMDY5NXpYU1Vqc1ZCeTlGVHBpZ0dfeW5ISDdSQ2RWYmI0NFJEWnlMTS1LdWpNUjlyMUNKbC1BMk4wT0RDeUJKX2tOZkRQYmlHWnZMdHFkTVE2S1hWRkpkLWJLcm5GUFpTM0NsVG11SEtPbzRtcnNwdE1wbmZadnlqZUJ3dEMyXzVKa21IQ0E?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Alkermes Plc (ALKS) by business segment and by region, with data current as of April 6. The report highlights key product contributions such as VIVITROL, ARISTADA, and LYBALVI, which together account for a significant portion", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alks/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:28", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQzlnQkFSVXlWeVR5MGxaLVZyZzMyM1UyRnVydGhwdGFHa1pmcFZ2TXd3T25TUjFqUFhvRzlQTXpqNU16LVNielVIa0NxNzh4cnNCWHRCamh5MFNqRnBCR0lZVXBOUTY2UU5sLURiTlloQ2FQZm1rejJkNUxkOWJzVjBWTjRNUmtWTjdwVTRUNW4tSEQ0V2V0RjdRR0NESGVBckYzUk1PWXBnbXY0MVFldWtxYUhYM09ENFdhX3p0a25lTFYweFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes\u2019 alixorexton receives orphan drug designations in US, EU", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQX0hjanBqZmtBTENRZUd4R1hVcV9yTHNiRlRRdGhLWC1WV2hXVkJ5YlNUNkZTU2NHRW83NDJCcWlzVnBSWUtJMGg5ZndsXzItdWNxNWc2dHRNWjdRT0VpcDFPRXBnRXFLendObVRhWThSVkpMekFJcTFpbFVMNG5CMWdFdG13cklNb1RTMHVLd01NZHQ5eTQ0N2htZXJQS1ZzcEpuOVlLcnVwNllKTWJJMEs3dDBVNmcwejFQRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan", "summary": "Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at $45.10 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Wright directly holds 25,680 Ordinary Shares. The sale amount", "url": "https://www.stocktitan.net/sec-filings/ALKS/form-4-alkermes-plc-insider-trading-activity-bf3febe786ad.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:18:23", "published_display": "13 Jun 2026 00:18", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors", "summary": "Alkermes PLC (ALKS) shares surged 4.4% to $44.28 on June 9, 2026, driven by strong momentum despite being identified as significantly overvalued by GuruFocus's GF Value\u2122 methodology. The company holds an above-average GF Score\u2122 of 74/100, though its financial strength and profita", "url": "https://www.gurufocus.com/news/8908952/alkermes-plc-alks-shares-surge-44-what-gf-score-of-74-tells-investors", "source_name": "GuruFocus", "published_at": "2026-06-10T00:39:25", "published_display": "10 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at 44.58 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPM0ZWcEtIYXBJNkxGSm14RGhFQjBKWkJJXzZPUnY2QkY0cmRlMXc3cFNaRzdYbExMSHJkeDMyVGJuNUZVR0R1alowVWV6ZmxVckxEYmFMd2R6RURmd00tTHdOTmV1US1BVGFjQkc5eE01WnR5RDI0NFhrdEt4VkhxZjNZdXpsQmpiZ2dTelBLM1ZYUU1wTEJOb05PVDRHMDJKVmc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan", "summary": "David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes plc (ALKS), reported an open-market sale of 2,034 Ordinary Shares at an average price of $43.05 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November", "url": "https://www.stocktitan.net/sec-filings/ALKS/form-4-alkermes-plc-insider-trading-activity-e6b129c9f67d.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:00:04", "published_display": "04 Jun 2026 21:00", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?", "summary": "Alkermes (ALKS) has seen its shares increase by 21.1% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss and beat revenue estimates, driven by strong sales of its proprietary products like Vivitrol, Aristada, Lyba", "url": "https://sg.finance.yahoo.com/news/alkermes-alks-21-1-since-153006247.html", "source_name": "Market source", "published_at": "2026-06-04T15:30:00", "published_display": "04 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference", "summary": "Alkermes plc (ALKS) announced its participation in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The company's management will present at the conference on June 11, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available on the Alkermes ", "url": "https://www.msn.com/en-us/money/general/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference/ar-AA24LZHq?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-04T01:09:22", "published_display": "04 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSG5QU0RuZHNXbXRHTTBPWTZ1SEpNelpFelVCdlJKckhTeUY1RWljQmw3WXlac1gtNWVXa2NqZ3MxVy1ZelczWWFnVTFEY3NKUkpVY05jY2NLLXVkalpna0t1RWw2eG92eEF0Z0E4NzhCSTc2REdCMVhiTHlJWnhoZ2lKZEF3V0pwWHUxSnMyN0lLeGZDRFRzY01nbjZ6VEVHeGRQaU84b1pYOUpqYTFTUF9PM2pLZmxw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) finance VP exercises options and sells 16,217 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQ1hDVldrN1ZFc2p4TlVLZFpuSTVEdEQzMVM2cGUweXEzenR0ZUZycTJIZVU1YWU3QXQ2SE1HREtEVlZIZW1sVWF1WkxHOGVZTUV0Y3BUS3d0Qm5WbzNQT2JiVXdRTlZyZVJVYlVwYTQ3cFYxOGxRU1F3bFVYOWpSNE9zLVZ5aEJFQ193Wng4OFgtLXBtRDRvaUhmUDRmY1JiZFhORGxjeklJQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting", "summary": "Alkermes plc announced it will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations will feature clinical and real-world data from their psychiatry and orexin portfolios, including commercial medicines LYBALVI and ARISTADA, a", "url": "https://www.businesswire.com/news/home/20260526269528/en/Alkermes-to-Showcase-Leadership-in-Psychiatry-and-Orexin-Biology-With-New-Data-at-the-American-Society-of-Clinical-Psychopharmacology-Annual-Meeting", "source_name": "Business Wire", "published_at": "2026-05-27T08:09:15", "published_display": "27 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences", "summary": "Alkermes will present data from its psychiatry portfolio and sleep research at various scientific conferences in the spring of 2026. These presentations will include a focus on real-world patient experiences, highlighting the company's commitment to advancing treatments in these ", "url": "https://www.msn.com/en-us/health/other/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences/ar-AA23IPmp?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T17:09:44", "published_display": "21 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at $38.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdk1RZGVHeDZSSldST0w3ME1rd1RPR2p3MVg4cExjMFJNYThCbjNrUHE0YkFzSmdkeW1hc2pZZlQyVncxTzFOTXVHNzg0VVl2eXpsaHJ4Vi1VRDBqMDY0TmxER2FNU1VMc21rVGRLS1dWWW5tajExRzZoNXo5Q3EzZ205SXFHWE5RbTQ2Nl9KZ0Y5Wmx0NlZvdDJhR0s?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSWJscDMyQVhRTng2eWs5V21WYUFTcmVOb1ZlbnVtOWpfaThsYXp3RGJwOGhBM3FBTFhvY2ZyTGxpQXgtU0E0NzNzNE9ndEc5TEdkUU5oMXJLM29jUUk5NTBwM18wUWRJNndhWlVUenMwSUZ3RnR2YnQwYkxlc1ducTE5al9UZzA?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH", "summary": "Alkermes anticipates increased value from its acquisition of Avadel Pharmaceuticals following positive Phase III results for Lumryz in idiopathic hypersomnia (IH). However, due to a settlement with Jazz Pharmaceuticals, the launch of Lumryz is delayed until 2028. This development", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/alkermes-sees-upside-to-its-avadel-buy-with-phase-iii-lumryz-win-in-ih-6WH3Q3XDQJC4BIRGZVVNHEGKCI/", "source_name": "Citeline News & Insights", "published_at": "2026-05-12T22:39:58", "published_display": "12 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023", "summary": "Alkermes plc is scheduled to report its fourth quarter and year-end financial results on February 16, 2023. The company's recent activities include various SEC filings, insider transactions, and upcoming financial results announcements for different quarters, as tracked by Quanti", "url": "https://www.quantisnow.com/insight/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-4033746", "source_name": "Quantisnow", "published_at": "2026-05-12T18:10:21", "published_display": "12 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz", "summary": "Alkermes plc announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release for adults with idiopathic hypersomnia. The study met its primary endpoint, demonstrating robust efficacy for the treatment. This development", "url": "https://www.marketscreener.com/news/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryz-ce7f5bdedb81fe22", "source_name": "marketscreener.com", "published_at": "2026-05-12T11:09:58", "published_display": "12 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises", "summary": "Alkermes (ALKS) reported strong first-quarter 2026 results, surpassing both earnings and revenue estimates. This positive financial performance led to a rise in the company's stock. The robust Q1 outcomes indicate a favorable outlook for the pharmaceutical company.", "url": "https://www.msn.com/en-us/money/topstocks/alkermes-q1-earnings-revenues-beat-estimates-stock-rises/ar-AA22xsfv", "source_name": "MSN", "published_at": "2026-05-11T11:08:42", "published_display": "11 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Alkermes (ALKS) After Strong Recent Share Price Gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Margin Compression Tests Bullish Earnings Growth Narratives Ahead Of Q1 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPVk10aTM4LVdxX3VnOHZDaXlfSFpWckNQdlpkUHg2OXpiOXZVVHhKUDYzS3dDMHNXY1lDZFJBY3pMbVRCS2ZyX2ktRmJPek40STFwNkFMUVJXOC1DdnYzbDM5LU1uUnhmRWhZZVVJdld1YTZYcmotcVRfcWU4OXY1RTFRbGFpS2hlWE5XMXR2V05OaTg3WVhGLWU1d1NfSjZ5Q2pfbDBab1FKTnE5VlEzanZSMllUUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOUVBBZEZlYXZBcGtjaTZlMlNPX2I2RDVqZ09DU3dhODFrRGxjYkw1YkRZU2F4d2JtU1ZvYzRYTEp4ZTZFTkFnTkVmTE5tQnQ2SS1NamZyNHB3anJwWW9zOGY5blVnV0VfakFqZnFCWEVTMk5MX1FBdVg2bzlJOHJVRDZxVXh5RTdTWUtUOWdpVlY4Wk5rUWxXVXBUX2RPQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOMkw0QlpsazhHMkh5cTRNa0dFcnNxU0NoM3pubEl1ZllKb2lWOTEwdTk3SFZPMHgxQUVwWWJ3eUpCcjhIaFNic3h4anJGN2hwNGRmcVp6UUlmRVhPOVhTTmR3Vm91Q1Q0ZWJDS2tGSHAwUlBEY0F4NFR1TWhRaTZBMFVZeGhEcmlwWkpaSzh6Vm1lMXpzTW5xdHQwbFZhUmc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALKS Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides an in-depth financial analysis of Alkermes Plc (ALKS), including its income statement, balance sheet, cash flow statement, and key financial ratios through FY2025. It highlights the company's strong cash generation despite a decline in sales, maintaining hig", "url": "https://www.stocktitan.net/financials/ALKS/", "source_name": "Stock Titan", "published_at": "2026-04-22T17:09:55", "published_display": "22 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report First Quarter Financial Results on May 5, 2026", "summary": "Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested part", "url": "https://news.futunn.com/en/post/71884553/alkermes-to-report-first-quarter-financial-results-on-may-5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-04-22T16:09:50", "published_display": "22 Apr 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS", "summary": "Tudor Investment Corp ET AL has acquired a new stake in Alkermes plc (NASDAQ:ALKS), purchasing 56,383 shares valued at approximately $1.69 million in the third quarter. Despite this institutional interest and other funds increasing their positions, insiders have been selling shar", "url": "https://www.marketbeat.com/instant-alerts/filing-tudor-investment-corp-et-al-takes-position-in-alkermes-plc-alks-2026-04-13/", "source_name": "MarketBeat", "published_at": "2026-04-13T12:10:08", "published_display": "13 Apr 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Alkermes plc. SEC Filing", "summary": "This article reports on an ARS filing by Alkermes plc. (ALKS) on April 6, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to Alkermes. The company's stock data, incl", "url": "https://www.stocktitan.net/sec-filings/ALKS/ars-alkermes-plc-sec-filing-a639920fbf97.html", "source_name": "Stock Titan", "published_at": "2026-04-10T15:39:40", "published_display": "10 Apr 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Advances Alixorexton into Phase 3 Trials for Narcolepsy Treatment", "summary": "Alkermes (ALKS) has advanced alixorexton, an experimental oral treatment, into Phase 3 Brilliance Studies for narcolepsy types 1 and 2, building on positive Phase 2 results. The biotechnology company, with a market capitalization of $5.89 billion, demonstrates strong financial he", "url": "https://www.gurufocus.com/news/8763724/alkermes-alks-advances-alixorexton-into-phase-3-trials-for-narcolepsy-treatment?mobile=true", "source_name": "GuruFocus", "published_at": "2026-04-01T18:41:15", "published_display": "01 Apr 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQTHh1QlkteTlHUW13OVJvTmZfUGxKSXRZX1F4R1pCRGp5dVlsenlMd2ZBeGFvdVNBX3RDakh4MzFwM2c2VS1RNXFGdE5SVDE0Z1Q2azVRd3gtRnRYX2huVGpWVEZoNlFtUnJZOXRidE9sM1VUdHNUTHd1N2JtUzBtbTNWU1FsMGtYZTltSUE1aXdING8?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Reveals CEO Succession Plan Following Richard Pops\u2019 Retirement Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNVmc5cVZaOUdHdktnR1lpZkJINkl6dVdlNDlpT0N1Z1JnTWF4WVlGaUVaX19jRUpfTS1HRGVsZFBYRW45N0V3ajZ5Wjl4d0ZuT1pjeUpKblh6bldXSTh0RW1iN3JJRU8zcGxVVk1fTWI1YjRGRzQ5am5wWEl6NGZSeHRvU09BY2NnY0NjbVFsaXpNTGpzYS1JNkp1SEN3Z1pjLW9Wc0kxTXdRNEhEcHE4NVFNa3g?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating", "summary": "Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel P", "url": "https://www.marketscreener.com/news/deutsche-bank-adjusts-alkermes-price-target-to-42-from-43-maintains-buy-rating-ce7e5ddedf81f221", "source_name": "marketscreener.com", "published_at": "2026-02-18T12:58:25", "published_display": "18 Feb 2026 12:58", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeHlnVkRVNV9fX0l6THAxY0F5QVdMTldVWTgybU9EdEUtbFA2X1NmUmUwS2xhY2lkZkZ0NkEwNzluM0NFTVZITWpoamhUTWlGdjUwZEFGUGRpaUhDVGJBTHlYX0x2Uy1pT28wd2pjV093U1k5NDgtV0hVSTJNeEhSMkloSnpJWndIZGs4?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?", "summary": "Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks ", "url": "https://finviz.com/news/313197/will-alkermes-alks-beat-estimates-again-in-its-next-earnings-report", "source_name": "Finviz - Stock Screener", "published_at": "2026-02-17T18:27:45", "published_display": "17 Feb 2026 18:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential", "summary": "Alkermes plc (NASDAQ: ALKS) is highlighted as a compelling investment due to strong buy ratings and a projected 32.12% upside potential. The biopharmaceutical company, with a market cap of $5.48 billion, focuses on proprietary products for neurological disorders and mental health", "url": "https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-strong-buy-ratings-and-a-promising-32-upside-potential/4121240084", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-16T19:58:25", "published_display": "16 Feb 2026 19:58", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ireland's Alkermes plc buys Avadel Pharmaceuticals plc", "summary": "Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc for $2.3 billion in cash and debt, incorporating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic move expands Alkermes' presence in sleep medicine, enhances its p", "url": "https://www.alchempro.com/news/chemicals-news/ireland-s-alkermes-plc-buys-avadel-pharmaceuticals-plc-308446-newsdetails.htm", "source_name": "ALCHEMPro", "published_at": "2026-02-16T19:28:17", "published_display": "16 Feb 2026 19:28", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS", "summary": "The Public Sector Pension Investment Board increased its stake in Alkermes plc by 11.6% in the third quarter, now owning 710,700 shares valued at $21.32 million. Institutional investors collectively own 95.21% of Alkermes stock. Analysts have a \"Moderate Buy\" consensus rating for", "url": "https://www.marketbeat.com/instant-alerts/filing-public-sector-pension-investment-board-has-2132-million-stock-holdings-in-alkermes-plc-alks-2026-02-14/", "source_name": "MarketBeat", "published_at": "2026-02-14T11:27:24", "published_display": "14 Feb 2026 11:27", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market", "summary": "Alkermes PLC has announced the completion of its acquisition of Avadel Pharmaceuticals PLC. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market. The news was reported by Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA1J0LSJ:0-alkermes-plc-completes-acquisition-of-avadel-pharmaceuticals-plc-accelerating-entry-into-sleep-medicine-market/", "source_name": "TradingView", "published_at": "2026-02-12T14:56:58", "published_display": "12 Feb 2026 14:56", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement", "summary": "Alkermes plc, along with Alkermes, Inc. and Alkermes Finance LLC, has entered into a credit agreement providing for two senior secured term loan facilities totaling $1.525 billion. These facilities, a $750 million TLA Facility and a $775 million TLB Facility, mature in February 2", "url": "https://www.marketscreener.com/news/alkermes-inc-alkermes-inc-and-alkermes-finance-llc-enters-into-credit-agreement-ce7e5ad3d889f425", "source_name": "marketscreener.com", "published_at": "2026-02-12T13:56:58", "published_display": "12 Feb 2026 13:56", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans", "summary": "Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA-approved narcolepsy drug LUMRYZ and a specialized commercial team for sleep medicine. The deal involves an all-cash payment of $21.00 per share plus a contingent value right for Avadel share", "url": "https://www.stocktitan.net/sec-filings/ALKS/8-k-alkermes-plc-reports-material-event-433502ac24a7.html", "source_name": "Stock Titan", "published_at": "2026-02-12T12:56:58", "published_display": "12 Feb 2026 12:56", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T05:04:10+00:00", "published_display": "16 Jul 2026 05:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report Second Quarter Financial Results on July 28, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-report-second-quarter-financial-200000876.html", "source_name": "Business Wire", "published_at": "2026-07-14T20:00:00+00:00", "published_display": "14 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study", "summary": "Alkermes plc (NASDAQ: ALKS) announced positive interim results from its long-term extension study of alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue for adults with narcolepsy type 1 and 2. Participants in both groups demonst", "url": "https://www.sahmcapital.com/news/content/alkermes-says-lead-drug-maintains-wakefulness-benefits-in-long-term-narcolepsy-study-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T13:40:41", "published_display": "14 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Alkermes(ALKS.US) With Buy Rating, Raises Target Price to $62", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQblJsN0d4cU1QX3hsV1FNZkJ6bGF0Q3hMbURnOHVQRjhuRUU4RF9FVmZjcEFQZm5zdWdHUjNvekdSN3lVUHpZOVhBOGl2QjJTMzM4YWdYUkQtUmFZSjZGcXBxNzNwT0REd3V2WHhQZVlrSW5LZkdZUlRUS2xSRmItN3NhNWRsUmZZZGM4OVRmQzVTZFVWYXoxdXJ5N2Izc3NvY1kxVUJwTDVTcnFha05raQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T09:48:01+00:00", "published_display": "14 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPc1BKVFJFM0RiYWNEbjl3dXlnNDR6T1lJWWtEanQ4VkZTaG9GQWNycVN5el80eVB3d3FBcng1TFpiSkNBOC1hLUoxQzEyZTVXZGxDQTAwREF2M1V0TjVCa0sycDJqQi1Tb05TNmd1bFp5MGotR3V6ODY3czNpTzJJRk9aLVpuaUxGTkxXSEJSMG5acC02dXIxc3RjTkljbTZPc25kWlVZTGYzeHBrcWIxd2FEZ2xGdXE3UkQ0MkRadjE?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-13T15:03:43+00:00", "published_display": "13 Jul 2026 15:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-public-apos-alixorexton-demonstrates-120109047.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:01:09+00:00", "published_display": "13 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes\u2019 Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-alixorexton-demonstrated-sustained-improvement-110000199.html", "source_name": "Business Wire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental narcolepsy pill from Alkermes keeps patients awake and alert for up to nine months", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOQzRMZ1A2YmZzdWEtbkVDT1J3M0tBZlp4d1BDUGJwMFpRUDU0alFpOFNrMWFRTHNFMHNjcFhWTEl4WTJWUVVtNm1hVjJjR2ZBRXp0RlRiMk5qZkdFYkpDZFFISzAyRDR6d1k4UVVNZGczdVZ3bUR5VUNlcHNrNFRHbXVoSF8yUW1iTlV5ellKa3JIYlV4ZlpNV1NaRnpFSGFhbTNLQWM2VzdfSVBRRlBTbzdXOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes Alkermes stock coverage with neutral rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbFNJMnpqQm5mbHpGenV5NGNrTC1YVXA3RHFUaXF0ZmQyOHBRSnhaQ3JmU1Z0N2ljNzFhRTJpejd0MWNWQm1LY0Jsd0dnZDdSZVE2OFdINTMzTlJaSDdKUGxZRFFWdzZVX0RxbGt0MUJpbE1NM0NpbGxHUjFTOExVZGpUVE1iV1FzMHZEaXlVS1Zpc0tYcXlQdHJEd25NNm1qd3FrUGJFVjZBbXFCRVpYaWdWS2FBSEVOLWRaWlZB?oc=5", "source_name": "Investing.com Australia", "published_at": "2026-07-13T08:52:04+00:00", "published_display": "13 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF S", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObnlqUm53SXFHMDlrbnVkVTZQTVVIRWNLVko0UElZSFFVYjltaVRKaDB0V1NuWEF6akFkZmQzRkhMY2wtc2xXMnNjTXNSWHp0VWtPTThlYjVLRkhySFhmWEpLdzQ5YmhkVmIxUjRRWEZNcHMyMEliRTFqVVF5OXhaZm9GOUFqZzF2NWRkNm9KU3BUM283TE4yRlNtWGNMT05xcW1KX1ZaX0xnSWUwUkhBZVV0eVBPSUhpeUE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T21:56:14+00:00", "published_display": "10 Jul 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T05:00:40+00:00", "published_display": "09 Jul 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOTThvVGppREZYQ3A0SHluRzZyTTdDTkVKN2M5MlpPOFc0SUtCLV9nOEJUVUlVZTR4MW0ycFBXV3pHdHZoX0dOam5tRlVWUmdqNmJxZ0x3MTR1cUgwTk1ES01aN3lwendmaXFsa2FvMnphYzFHd2hCUjNkUm5FWG1sQk5VQVRKMmlIV3V4dVpfZ0MxSTlGMDRHVWNveGtKM2QzZGQ1bS1TSkVmQ2xqX3d0bkFIWklKdzVXb2x0VlozOGJSOWVrYUJ5RXNDeW1jTjg3QWFVb3ZRc2JoZ9IB3wFBVV95cUxPc3BKWnEwVVZaSXdJUHlCWTl6c19LSnZXV3JmMmR4azFpa2w4UURsTERVVmZ4bFlSdWVQak95VXBGRTlYWVp6RVhIMGVDZEpDRWFnZ25aTW9XZ1FpMFQ5ZFBhN2xkNld2TmNzZUVwd09zaWFtSU1kTVZYLUZKV2gtU29peWZQVEh5dkQycV9fWkZpLXJ1Y1B6cXVFS2d1dGV3dG14Zkh6Mm5IUWx1V0RUb29tRDhUZWoxSWxIb0lUVEtSTHZxc2hLOW5zU19TWFc2Y0xFU2N4SFh3dE9JYmdZ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Insider Sold Shares Worth $463,621, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alkermes-insider-sold-shares-worth-081501424.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:15:01+00:00", "published_display": "02 Jul 2026 08:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 Addition - What's Changed", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alkermes-alks-9-3-strong-140702068.html", "source_name": "Simply Wall St.", "published_at": "2026-06-30T14:07:02+00:00", "published_display": "30 Jun 2026 14:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Stock 7-Day Winning Spree: Stock Climbs 25%", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQOVVYaFpnRW9QNHZySEIyVEw5WnlrTVdWSm12aHh3MkVyVTFMQzdqNGhFaW5iVWxTUXlxSGE5RV9xR28wRzhhT2ZXUGJkTVJJMTFSM2w3WFRqOGQ5Qmx4eEsyaGNaY2F4bzU2enJJMVpjaVFnTS1Ma0JvYnljTm9Oc24td2EzeGxKaHBJU0NWcS1Ib1NqaGxJdGIxVmlMR3c1SGJXMWp2cFdfN0ZxbzI0Xw?oc=5", "source_name": "Trefis", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alkermes plc \u2013 NASDAQ:ALKS", "summary": "This article focuses on the enterprise value to EBIT forward for Alkermes plc (NASDAQ: ALKS). It appears to be a financial data point or analysis page from TradingView, providing an overview of this specific financial metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALKS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:40:29", "published_display": "28 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Stock On Fire: Up 25% With 7-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWlFpM0FQSE5MS0hjVTJSM2FPY1RRUWRHSzY1a3pGRlFRUUJWZlZWUWgtR1YtSlhjQmhPSXBEWjN3c3hQaFlkSjZZSHB1Q2s1RzktRWJ3OUhOQVRycWNNNHpYa3N0TDhRTm1XbHhJYkc1eGZQSHNtT3hKajIzTVVicW9tV3pqeHB4Z0lzal9WdDZreGZpdjk1akRrcXMxZkJVRGJfbVcxRmNVQkd3bjhRNTBPdVBsQ2tYV0JtOHR4a3g1UQ?oc=5", "source_name": "Trefis", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at 45.76 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOSnU0WXlhLXRFWEhpZE50Vk93QlVLMDY5NXpYU1Vqc1ZCeTlGVHBpZ0dfeW5ISDdSQ2RWYmI0NFJEWnlMTS1LdWpNUjlyMUNKbC1BMk4wT0RDeUJKX2tOZkRQYmlHWnZMdHFkTVE2S1hWRkpkLWJLcm5GUFpTM0NsVG11SEtPbzRtcnNwdE1wbmZadnlqZUJ3dEMyXzVKa21IQ0E?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Alkermes Plc (ALKS) by business segment and by region, with data current as of April 6. The report highlights key product contributions such as VIVITROL, ARISTADA, and LYBALVI, which together account for a significant portion", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alks/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:28", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQzlnQkFSVXlWeVR5MGxaLVZyZzMyM1UyRnVydGhwdGFHa1pmcFZ2TXd3T25TUjFqUFhvRzlQTXpqNU16LVNielVIa0NxNzh4cnNCWHRCamh5MFNqRnBCR0lZVXBOUTY2UU5sLURiTlloQ2FQZm1rejJkNUxkOWJzVjBWTjRNUmtWTjdwVTRUNW4tSEQ0V2V0RjdRR0NESGVBckYzUk1PWXBnbXY0MVFldWtxYUhYM09ENFdhX3p0a25lTFYweFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes\u2019 alixorexton receives orphan drug designations in US, EU", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQX0hjanBqZmtBTENRZUd4R1hVcV9yTHNiRlRRdGhLWC1WV2hXVkJ5YlNUNkZTU2NHRW83NDJCcWlzVnBSWUtJMGg5ZndsXzItdWNxNWc2dHRNWjdRT0VpcDFPRXBnRXFLendObVRhWThSVkpMekFJcTFpbFVMNG5CMWdFdG13cklNb1RTMHVLd01NZHQ5eTQ0N2htZXJQS1ZzcEpuOVlLcnVwNllKTWJJMEs3dDBVNmcwejFQRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan", "summary": "Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at $45.10 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Wright directly holds 25,680 Ordinary Shares. The sale amount", "url": "https://www.stocktitan.net/sec-filings/ALKS/form-4-alkermes-plc-insider-trading-activity-bf3febe786ad.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:18:23", "published_display": "13 Jun 2026 00:18", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors", "summary": "Alkermes PLC (ALKS) shares surged 4.4% to $44.28 on June 9, 2026, driven by strong momentum despite being identified as significantly overvalued by GuruFocus's GF Value\u2122 methodology. The company holds an above-average GF Score\u2122 of 74/100, though its financial strength and profita", "url": "https://www.gurufocus.com/news/8908952/alkermes-plc-alks-shares-surge-44-what-gf-score-of-74-tells-investors", "source_name": "GuruFocus", "published_at": "2026-06-10T00:39:25", "published_display": "10 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at 44.58 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPM0ZWcEtIYXBJNkxGSm14RGhFQjBKWkJJXzZPUnY2QkY0cmRlMXc3cFNaRzdYbExMSHJkeDMyVGJuNUZVR0R1alowVWV6ZmxVckxEYmFMd2R6RURmd00tTHdOTmV1US1BVGFjQkc5eE01WnR5RDI0NFhrdEt4VkhxZjNZdXpsQmpiZ2dTelBLM1ZYUU1wTEJOb05PVDRHMDJKVmc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan", "summary": "David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes plc (ALKS), reported an open-market sale of 2,034 Ordinary Shares at an average price of $43.05 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November", "url": "https://www.stocktitan.net/sec-filings/ALKS/form-4-alkermes-plc-insider-trading-activity-e6b129c9f67d.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:00:04", "published_display": "04 Jun 2026 21:00", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?", "summary": "Alkermes (ALKS) has seen its shares increase by 21.1% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss and beat revenue estimates, driven by strong sales of its proprietary products like Vivitrol, Aristada, Lyba", "url": "https://sg.finance.yahoo.com/news/alkermes-alks-21-1-since-153006247.html", "source_name": "Market source", "published_at": "2026-06-04T15:30:00", "published_display": "04 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference", "summary": "Alkermes plc (ALKS) announced its participation in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The company's management will present at the conference on June 11, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available on the Alkermes ", "url": "https://www.msn.com/en-us/money/general/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference/ar-AA24LZHq?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-04T01:09:22", "published_display": "04 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSG5QU0RuZHNXbXRHTTBPWTZ1SEpNelpFelVCdlJKckhTeUY1RWljQmw3WXlac1gtNWVXa2NqZ3MxVy1ZelczWWFnVTFEY3NKUkpVY05jY2NLLXVkalpna0t1RWw2eG92eEF0Z0E4NzhCSTc2REdCMVhiTHlJWnhoZ2lKZEF3V0pwWHUxSnMyN0lLeGZDRFRzY01nbjZ6VEVHeGRQaU84b1pYOUpqYTFTUF9PM2pLZmxw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) finance VP exercises options and sells 16,217 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQ1hDVldrN1ZFc2p4TlVLZFpuSTVEdEQzMVM2cGUweXEzenR0ZUZycTJIZVU1YWU3QXQ2SE1HREtEVlZIZW1sVWF1WkxHOGVZTUV0Y3BUS3d0Qm5WbzNQT2JiVXdRTlZyZVJVYlVwYTQ3cFYxOGxRU1F3bFVYOWpSNE9zLVZ5aEJFQ193Wng4OFgtLXBtRDRvaUhmUDRmY1JiZFhORGxjeklJQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting", "summary": "Alkermes plc announced it will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations will feature clinical and real-world data from their psychiatry and orexin portfolios, including commercial medicines LYBALVI and ARISTADA, a", "url": "https://www.businesswire.com/news/home/20260526269528/en/Alkermes-to-Showcase-Leadership-in-Psychiatry-and-Orexin-Biology-With-New-Data-at-the-American-Society-of-Clinical-Psychopharmacology-Annual-Meeting", "source_name": "Business Wire", "published_at": "2026-05-27T08:09:15", "published_display": "27 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences", "summary": "Alkermes will present data from its psychiatry portfolio and sleep research at various scientific conferences in the spring of 2026. These presentations will include a focus on real-world patient experiences, highlighting the company's commitment to advancing treatments in these ", "url": "https://www.msn.com/en-us/health/other/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences/ar-AA23IPmp?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T17:09:44", "published_display": "21 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes stock hits 52-week high at $38.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdk1RZGVHeDZSSldST0w3ME1rd1RPR2p3MVg4cExjMFJNYThCbjNrUHE0YkFzSmdkeW1hc2pZZlQyVncxTzFOTXVHNzg0VVl2eXpsaHJ4Vi1VRDBqMDY0TmxER2FNU1VMc21rVGRLS1dWWW5tajExRzZoNXo5Q3EzZ205SXFHWE5RbTQ2Nl9KZ0Y5Wmx0NlZvdDJhR0s?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSWJscDMyQVhRTng2eWs5V21WYUFTcmVOb1ZlbnVtOWpfaThsYXp3RGJwOGhBM3FBTFhvY2ZyTGxpQXgtU0E0NzNzNE9ndEc5TEdkUU5oMXJLM29jUUk5NTBwM18wUWRJNndhWlVUenMwSUZ3RnR2YnQwYkxlc1ducTE5al9UZzA?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH", "summary": "Alkermes anticipates increased value from its acquisition of Avadel Pharmaceuticals following positive Phase III results for Lumryz in idiopathic hypersomnia (IH). However, due to a settlement with Jazz Pharmaceuticals, the launch of Lumryz is delayed until 2028. This development", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/alkermes-sees-upside-to-its-avadel-buy-with-phase-iii-lumryz-win-in-ih-6WH3Q3XDQJC4BIRGZVVNHEGKCI/", "source_name": "Citeline News & Insights", "published_at": "2026-05-12T22:39:58", "published_display": "12 May 2026 22:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023", "summary": "Alkermes plc is scheduled to report its fourth quarter and year-end financial results on February 16, 2023. The company's recent activities include various SEC filings, insider transactions, and upcoming financial results announcements for different quarters, as tracked by Quanti", "url": "https://www.quantisnow.com/insight/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-4033746", "source_name": "Quantisnow", "published_at": "2026-05-12T18:10:21", "published_display": "12 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz", "summary": "Alkermes plc announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release for adults with idiopathic hypersomnia. The study met its primary endpoint, demonstrating robust efficacy for the treatment. This development", "url": "https://www.marketscreener.com/news/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryz-ce7f5bdedb81fe22", "source_name": "marketscreener.com", "published_at": "2026-05-12T11:09:58", "published_display": "12 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises", "summary": "Alkermes (ALKS) reported strong first-quarter 2026 results, surpassing both earnings and revenue estimates. This positive financial performance led to a rise in the company's stock. The robust Q1 outcomes indicate a favorable outlook for the pharmaceutical company.", "url": "https://www.msn.com/en-us/money/topstocks/alkermes-q1-earnings-revenues-beat-estimates-stock-rises/ar-AA22xsfv", "source_name": "MSN", "published_at": "2026-05-11T11:08:42", "published_display": "11 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Alkermes (ALKS) After Strong Recent Share Price Gains", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Margin Compression Tests Bullish Earnings Growth Narratives Ahead Of Q1 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPVk10aTM4LVdxX3VnOHZDaXlfSFpWckNQdlpkUHg2OXpiOXZVVHhKUDYzS3dDMHNXY1lDZFJBY3pMbVRCS2ZyX2ktRmJPek40STFwNkFMUVJXOC1DdnYzbDM5LU1uUnhmRWhZZVVJdld1YTZYcmotcVRfcWU4OXY1RTFRbGFpS2hlWE5XMXR2V05OaTg3WVhGLWU1d1NfSjZ5Q2pfbDBab1FKTnE5VlEzanZSMllUUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOUVBBZEZlYXZBcGtjaTZlMlNPX2I2RDVqZ09DU3dhODFrRGxjYkw1YkRZU2F4d2JtU1ZvYzRYTEp4ZTZFTkFnTkVmTE5tQnQ2SS1NamZyNHB3anJwWW9zOGY5blVnV0VfakFqZnFCWEVTMk5MX1FBdVg2bzlJOHJVRDZxVXh5RTdTWUtUOWdpVlY4Wk5rUWxXVXBUX2RPQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOMkw0QlpsazhHMkh5cTRNa0dFcnNxU0NoM3pubEl1ZllKb2lWOTEwdTk3SFZPMHgxQUVwWWJ3eUpCcjhIaFNic3h4anJGN2hwNGRmcVp6UUlmRVhPOVhTTmR3Vm91Q1Q0ZWJDS2tGSHAwUlBEY0F4NFR1TWhRaTZBMFVZeGhEcmlwWkpaSzh6Vm1lMXpzTW5xdHQwbFZhUmc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALKS Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides an in-depth financial analysis of Alkermes Plc (ALKS), including its income statement, balance sheet, cash flow statement, and key financial ratios through FY2025. It highlights the company's strong cash generation despite a decline in sales, maintaining hig", "url": "https://www.stocktitan.net/financials/ALKS/", "source_name": "Stock Titan", "published_at": "2026-04-22T17:09:55", "published_display": "22 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes to Report First Quarter Financial Results on May 5, 2026", "summary": "Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested part", "url": "https://news.futunn.com/en/post/71884553/alkermes-to-report-first-quarter-financial-results-on-may-5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-04-22T16:09:50", "published_display": "22 Apr 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS", "summary": "Tudor Investment Corp ET AL has acquired a new stake in Alkermes plc (NASDAQ:ALKS), purchasing 56,383 shares valued at approximately $1.69 million in the third quarter. Despite this institutional interest and other funds increasing their positions, insiders have been selling shar", "url": "https://www.marketbeat.com/instant-alerts/filing-tudor-investment-corp-et-al-takes-position-in-alkermes-plc-alks-2026-04-13/", "source_name": "MarketBeat", "published_at": "2026-04-13T12:10:08", "published_display": "13 Apr 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] Alkermes plc. SEC Filing", "summary": "This article reports on an ARS filing by Alkermes plc. (ALKS) on April 6, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to Alkermes. The company's stock data, incl", "url": "https://www.stocktitan.net/sec-filings/ALKS/ars-alkermes-plc-sec-filing-a639920fbf97.html", "source_name": "Stock Titan", "published_at": "2026-04-10T15:39:40", "published_display": "10 Apr 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (ALKS) Advances Alixorexton into Phase 3 Trials for Narcolepsy Treatment", "summary": "Alkermes (ALKS) has advanced alixorexton, an experimental oral treatment, into Phase 3 Brilliance Studies for narcolepsy types 1 and 2, building on positive Phase 2 results. The biotechnology company, with a market capitalization of $5.89 billion, demonstrates strong financial he", "url": "https://www.gurufocus.com/news/8763724/alkermes-alks-advances-alixorexton-into-phase-3-trials-for-narcolepsy-treatment?mobile=true", "source_name": "GuruFocus", "published_at": "2026-04-01T18:41:15", "published_display": "01 Apr 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQTHh1QlkteTlHUW13OVJvTmZfUGxKSXRZX1F4R1pCRGp5dVlsenlMd2ZBeGFvdVNBX3RDakh4MzFwM2c2VS1RNXFGdE5SVDE0Z1Q2azVRd3gtRnRYX2huVGpWVEZoNlFtUnJZOXRidE9sM1VUdHNUTHd1N2JtUzBtbTNWU1FsMGtYZTltSUE1aXdING8?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes Reveals CEO Succession Plan Following Richard Pops\u2019 Retirement Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNVmc5cVZaOUdHdktnR1lpZkJINkl6dVdlNDlpT0N1Z1JnTWF4WVlGaUVaX19jRUpfTS1HRGVsZFBYRW45N0V3ajZ5Wjl4d0ZuT1pjeUpKblh6bldXSTh0RW1iN3JJRU8zcGxVVk1fTWI1YjRGRzQ5am5wWEl6NGZSeHRvU09BY2NnY0NjbVFsaXpNTGpzYS1JNkp1SEN3Z1pjLW9Wc0kxTXdRNEhEcHE4NVFNa3g?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating", "summary": "Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel P", "url": "https://www.marketscreener.com/news/deutsche-bank-adjusts-alkermes-price-target-to-42-from-43-maintains-buy-rating-ce7e5ddedf81f221", "source_name": "marketscreener.com", "published_at": "2026-02-18T12:58:25", "published_display": "18 Feb 2026 12:58", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeHlnVkRVNV9fX0l6THAxY0F5QVdMTldVWTgybU9EdEUtbFA2X1NmUmUwS2xhY2lkZkZ0NkEwNzluM0NFTVZITWpoamhUTWlGdjUwZEFGUGRpaUhDVGJBTHlYX0x2Uy1pT28wd2pjV093U1k5NDgtV0hVSTJNeEhSMkloSnpJWndIZGs4?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?", "summary": "Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks ", "url": "https://finviz.com/news/313197/will-alkermes-alks-beat-estimates-again-in-its-next-earnings-report", "source_name": "Finviz - Stock Screener", "published_at": "2026-02-17T18:27:45", "published_display": "17 Feb 2026 18:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential", "summary": "Alkermes plc (NASDAQ: ALKS) is highlighted as a compelling investment due to strong buy ratings and a projected 32.12% upside potential. The biopharmaceutical company, with a market cap of $5.48 billion, focuses on proprietary products for neurological disorders and mental health", "url": "https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-strong-buy-ratings-and-a-promising-32-upside-potential/4121240084", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-16T19:58:25", "published_display": "16 Feb 2026 19:58", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ireland's Alkermes plc buys Avadel Pharmaceuticals plc", "summary": "Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc for $2.3 billion in cash and debt, incorporating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic move expands Alkermes' presence in sleep medicine, enhances its p", "url": "https://www.alchempro.com/news/chemicals-news/ireland-s-alkermes-plc-buys-avadel-pharmaceuticals-plc-308446-newsdetails.htm", "source_name": "ALCHEMPro", "published_at": "2026-02-16T19:28:17", "published_display": "16 Feb 2026 19:28", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS", "summary": "The Public Sector Pension Investment Board increased its stake in Alkermes plc by 11.6% in the third quarter, now owning 710,700 shares valued at $21.32 million. Institutional investors collectively own 95.21% of Alkermes stock. Analysts have a \"Moderate Buy\" consensus rating for", "url": "https://www.marketbeat.com/instant-alerts/filing-public-sector-pension-investment-board-has-2132-million-stock-holdings-in-alkermes-plc-alks-2026-02-14/", "source_name": "MarketBeat", "published_at": "2026-02-14T11:27:24", "published_display": "14 Feb 2026 11:27", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market", "summary": "Alkermes PLC has announced the completion of its acquisition of Avadel Pharmaceuticals PLC. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market. The news was reported by Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA1J0LSJ:0-alkermes-plc-completes-acquisition-of-avadel-pharmaceuticals-plc-accelerating-entry-into-sleep-medicine-market/", "source_name": "TradingView", "published_at": "2026-02-12T14:56:58", "published_display": "12 Feb 2026 14:56", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement", "summary": "Alkermes plc, along with Alkermes, Inc. and Alkermes Finance LLC, has entered into a credit agreement providing for two senior secured term loan facilities totaling $1.525 billion. These facilities, a $750 million TLA Facility and a $775 million TLB Facility, mature in February 2", "url": "https://www.marketscreener.com/news/alkermes-inc-alkermes-inc-and-alkermes-finance-llc-enters-into-credit-agreement-ce7e5ad3d889f425", "source_name": "marketscreener.com", "published_at": "2026-02-12T13:56:58", "published_display": "12 Feb 2026 13:56", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans", "summary": "Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA-approved narcolepsy drug LUMRYZ and a specialized commercial team for sleep medicine. The deal involves an all-cash payment of $21.00 per share plus a contingent value right for Avadel share", "url": "https://www.stocktitan.net/sec-filings/ALKS/8-k-alkermes-plc-reports-material-event-433502ac24a7.html", "source_name": "Stock Titan", "published_at": "2026-02-12T12:56:58", "published_display": "12 Feb 2026 12:56", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 99, "total_relevant": 64, "sentiment_summary": {"positive": 23, "negative": 4, "neutral": 37, "score": 57, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 23, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 51.94, "latest_week": "2026-07-10", "one_week_move": -4.8, "four_week_move": 17.3, "twelve_week_move": 50.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.430571, "market_dynamics_buy_signal": false, "relative_strength": 36.597588, "fair_value_gap": 74.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.6509, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.8% over one week, +17.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "GuruFocus", "count": 3}, {"label": "MSN", "count": 3}, {"label": "marketscreener.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 64}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "64", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.8% over one week, +17.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)"}], "updated_at": "2026-07-16T08:53:02.594359+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}